Biotronik has announced US Food and Drug Administration (FDA) approval of the company’s MultiPole pacing (MPP) technology, designed to provide physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronisation therapy (CRT). MPP will be available on the company’s new CRT defibrillator (CRT-D) systems for patients with heart failure.
Nearly 40% of heart failure patients are initially non-responsive to CRT. This technology aims to address this challenge by enabling the left ventricle to be paced twice per cardiac cycle. These paces can be either sequential or simultaneous, intended to allow for greater customisation of therapy to meet specific patient needs.
“MultiPole Pacing is an important technology that allows physicians to tailor cardiac resynchronisation therapy to each patient,” says Gery Tomassoni, Baptist Health, Lexington, USA. “Heart failure is a complex condition and physicians are routinely challenged to find the ideal treatment for unique disease presentations. Adding MPP technology…creates more options for physicians to meet evolving patient needs.”